Hexa Reports Industry Spinal Muscular Atrophy (SMA) Market | Page 2

The Spinal Muscular Atrophy (SMA) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Spinal Muscular Atrophy (SMA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 4, 1, 13 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 2 molecules, respectively. Spinal Muscular Atrophy (SMA) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Request A Sample copy of This Report @ https://www.hexareports.com/report/spinal-muscular- atrophy-sma-pipeline-review-h2-2017/request-sample Scope The pipeline guide provides a snapshot of the global therapeutic landscape of Spinal Muscular Atrophy (SMA) (Central Nervous System). The pipeline guide reviews pipeline therapeutics for Spinal Muscular Atrophy (SMA) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry- specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre- registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The pipeline guide reviews key companies involved in Spinal Muscular Atrophy (SMA) (Central Nervous System) therapeutics and enlists all their major and minor projects. Reasons To Buy Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. Classify potential new clients or partners in the target demographic. Follow Us: